Read More

atai Life Sciences And Massachusetts General Hospital Announce Initiation Of Clinical Study Investigating Neuroplasticity Biomarkers In Treatment-Resistant Depression Patients Undergoing Ketamine Treatment

atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced it has initiated a clinical study

ATAI